Skip to main content

EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.

GAITHERSBURG, Maryland

Total Received

$2.34B

Total Awards

6

State

Maryland

Last Updated

Feb 11, 2026

Yearly Funding Trend

Top 6 Awards to EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.

Largest individual federal awards on record for this recipient, ranked by obligated amount. Data through February 11, 2026.

Download CSV
Top 6 Awards to EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
AwardAwarding AgencyProgramPlaceFYObligation
CONT_AWD_HHSO100201600030C_7505_-NONE-_-NONE-
EO14042 EMERGENT AV7909 ANTHRAX VACCINE
Department of Health and Human Services
Office of Assistant Secretary for Preparedness and Response
GAITHERSBURG, MD-062024$1,385,742,139
CONT_AWD_75A50119C00071_7505_-NONE-_-NONE-
ACAM2000, SMALLPOX (VACCINIA) VACCINE, LIVE (ACAM)
Department of Health and Human Services
Office of Assistant Secretary for Preparedness and Response
GAITHERSBURG, MD-062024$748,857,151
CONT_AWD_75A50123C00037_7505_-NONE-_-NONE-
THE PURPOSE OF THIS NO-COST MODIFICATION IS TO UPDATE SEVERAL ARTICLES.
Department of Health and Human Services
Office of Assistant Secretary for Preparedness and Response
GAITHERSBURG, MD-062024$118,563,679
CONT_AWD_HHSO100201500004C_7505_-NONE-_-NONE-
ADVANCED DEVELOPMENT OF NUTHRAX (ANTHRAX VACCINE ABSORBED WITH CPG 7909) OR AV7909
Department of Health and Human Services
Office of Assistant Secretary for Preparedness and Response
GAITHERSBURG, MD-062024$43,794,113
CONT_AWD_HHSO100201700001C_7505_-NONE-_-NONE-
PUT A STOP TO TASKS THAT ARE NO LONGER NEEDED
Department of Health and Human Services
Office of Assistant Secretary for Preparedness and Response
GAITHERSBURG, MD-062024$32,952,759
CONT_AWD_W81XWH19C0193_9700_-NONE-_-NONE-
ANALGESIC KETAMINE-CLINICAL TRIAL
Department of Defense
Department of the Army
GAITHERSBURG, MD-062024$5,721,771

Top 6 awards shown, ranked by obligated amount. Dates reflect performance period; last-modified dates match USAspending.gov. Complete listings include all transaction history going back to FY2024.